Aurinia Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Aurinia Pharmaceuticals Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Aurinia Pharmaceuticals Inc Strategy Report

  • Understand Aurinia Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Aurinia Pharmaceuticals Inc: Overview

Select Item

Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals) is a commercial-stage biopharmaceutical company. The company pipeline product includes voclosporin, lupkynis, AUR200 and AUR300. Its lupkynis is an orally administered CNI immunosuppressant, to treat adult patients with active lupus nephritis. Aurinia Pharmaceuticals voclosporin is used in clinical studies in patients with psoriasis, kidney transplantation, uveitis and dry eye syndrome indications. The company's AUR300 reduces M2 dysregulation and decreases inflammatory cytokines and finds clinical applications for autoimmune and fibrotic diseases. It collaborates with Otsuka Pharmaceutical Co., Ltd for the development and commercialization of oral voclosporin. The company operates in Canada and the US. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.

 Gain a 360-degree view of Aurinia Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Aurinia Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters Canada
Address #140, 14315 - 118 Avenue, Victoria, British Columbia, T5L4S6
Website www.auriniapharma.com
Telephone 1 250 7442487
No of Employees 300
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange AUPH (NASD)
Revenue (2022) $175.5M 31% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 27.9% (2022 vs 2021)
Market Cap* $710.1M
Net Profit Margin (2022) XYZ 44.9% (2022 vs 2021)
* As of and is in US$
View Aurinia Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Aurinia Pharmaceuticals Inc premium industry data and analytics

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Aurinia Pharmaceuticals Inc’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Aurinia Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Clinical Trials

Determine Aurinia Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

16+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

8

Pipeline Drugs

Identify which of Aurinia Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Aurinia Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Aurinia Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Pipeline
Voclosporin:
Lupus Nephritis (LN)
XYZ
XYZ
XYZ
Understand Aurinia Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Aurinia Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Plans/Strategy In June, the company announced its plans to consider a wide range of options for the company including a potential sale, merger, or other strategic transaction.
2023 Regulatory Approval In May, the company announced that Swissmedic approved marketing authorization of LUPKYNIS (voclosporin) for the development and commercialization of voclosporin for the treatment of lupus nephritis (LN).
2023 Others In April, the company issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Aurinia Pharmaceuticals Inc AbbVie Inc BioMarin Pharmaceutical Inc Zymeworks Inc Cipher Pharmaceuticals Inc
Headquarters Canada United States of America United States of America United States of America Canada
City Victoria North Chicago Novato Middletown Mississauga
State/Province British Columbia Illinois California Delaware Ontario
No. of Employees 300 50,000 3,401 272 6
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Daniel G. Billen Chairman Executive Board 2023 -
Peter Greenleaf Chief Executive Officer; President; Director Executive Board 2019 53
Joe Miller Chief Financial Officer Senior Management 2020 49
Stephen Robertson General Counsel; Executive Vice President; Secretary; Chief Compliance Officer Senior Management 2020 41
Scott Habig Chief Commercial Officer Senior Management 2022 63
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Aurinia Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Aurinia Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?